HIV Specialist Physicians, Infectious Disease Physicians
This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.
Supported by an independent educational grant from Gilead Sciences, Inc.
Release date: October 30, 2020
Expiration date: January 5, 2022
Estimated time to complete activity: 0.5 hours
This activity is intended for infectious disease and HIV specialist physicians and other clinicians involved in the care of patients with HIV infection.
Upon completion of this program, the participant should be better able to:
Women bear a significant burden in HIV, including increased risks for stigma or mental health disorders. Their treatment requirements can be unique when considering pregnancy and contraception. Though there are guidelines on routine monitoring, antepartum antiretroviral therapy (ART) regimens, and intra- and postpartum care, data are continuously evolving and clinicians must be aware of the most recent guidelines and treatment considerations for women. This case-based, interactive activity focuses on initiating ART during pregnancy, routine monitoring, viral suppression, considerations for delivery, contraception, and additional issues that arise for women with HIV, such as earlier menopause and low bone mineral density.
Rachel K. Scott, MD, MPH, FACOG
Scientific Director of Women's Health Research, MedStar Health Research Institute
Associate Chair for Research & Director of the Washington Women's Center for Positive Living, MedStar Washington Hospital Center Department of Women’s and Infants’ Services
Assistant Professor of Obstetrics and Gynecology, Georgetown University
Washington, District of Columbia
Elisa Ignatius, MD, MSc
Division of Infectious Diseases
Fellow, Division of Clinical Pharmacology
Johns Hopkins School of Medicine
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INSTRUCTIONS TO RECEIVE CREDIT
There are no fees for participating and receiving CME credit for this activity. During the period October 30, 2020 through October 30, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and posttest at the conclusion of the activity.
If you have questions regarding the receipt of your certificate, please contact PIM via email at firstname.lastname@example.org.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Rachel K. Scott, MD, MPH, FACOG
Contracted Research (paid to institution): Gilead Sciences, Inc.
Elisa Ignatius, MD, MSc
Nothing to disclose
The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
COURSE VIEWING REQUIREMENTS
|Supported Browsers: |
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above
For video playback, install the latest version of Flash or Quicktime.
|Supported Phones & Tablets: |
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above